UMASS Memorial Health Care
Worcester, Massachusetts, 01655, United States
NCT Number: NCT00946296
The purpose of this study is to determine whether a brief course of SSKI (saturated solution of potassium iodide) administered preoperatively provides any benefit in the surgical management of patients undergoing thyroidectomy as definitive management of their Graves Disease.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Worcester, Massachusetts, 01655, United States
Historically Potassium Iodide was given to patients for 1 week prior to thyroidectomy. This common practice was used to decrease thyroid function and prevent thyroid storm during the thyroidectomy. However, in modern practice, nearly all patients presenting for surgical management have been made euthyroid through the use of medications such as propylthiouracil. Despite this potassium iodine continues to be administered with the presumption that it decreases the friability of the gland making surgery easier, with less blood loss.
The outcomes to be measured in this surgery are operative time, operative complications and blood loss.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
8 drops of Potassium Iodide in a glass of water taken daily for 7 days prior to thyroidectomy. This is the current standard of care.
Other names: SSKI
Time frame: up to 162 minutes
Blood loss in milliliters during surgery.
University of Massachusetts, Worcester
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04932135
Autoimmune Diseases, Endocrine System Diseases
Basel, Switzerland
View Trial DetailsNCT04682340
Autoimmune Diseases, Endocrine System Diseases
Krakow, Malopolska, Poland
View Trial DetailsNCT05118542
Arterial Occlusive Diseases, Arteriosclerosis
Jakarta Pusat, Jakarta Special Capital Region, Indonesia
View Trial DetailsNCT00796913
Autoimmune Diseases, Endocrine System Diseases
View Trial Details